Top

Published in:

01-02-2015 | Original Article

CXCR4 is highly expressed at the tumor front but not in the center of prostate cancers

Authors: Nicolas Barry Delongchamps, Frédéric Beuvon, Jacques R. R. Mathieu, Stéphanie Delmas, Isabelle Metzger, Hervé Prats, Florence Cabon

Published in: World Journal of Urology | Issue 2/2015

Abstract

Objective

To evaluate the expression of CXCR4, its ligand SDF-1, β-catenin and E-cadherin throughout the local tumor microenvironment of prostate cancer.

Patients and methods

A total of 64 prostate cancer specimens, 24 frozen and 40 paraffin-embedded sections, were obtained from patients treated with radical prostatectomy for clinically localized cancer. Real-time RT-PCR was used for mRNA quantification of CXCR4 and SDF-1 in the tumor center (T), tumor front (F) and distant peritumoral tissue (D). Immunohistochemical analysis was used to investigate the expression patterns of CXCR4, E-cadherin and β-catenin. Clinical records of these patients were studied for follow-up data, and the prognostic value of these molecules’ expression was statistically assessed.

Results

CXCR4 mRNA and protein were significantly increased at the tumor front as compared to distant tissue or tumor center. In comparison, SDF-1 mRNA level gradually increased from the tumor center to the distant peritumoral tissue. High CXCR4 at the tumor front was associated with high Gleason score. Low SDF-1 at the tumor front was associated with locally advanced cancer and disease recurrence. Moreover, high CXCR4 staining at the tumor front and increased cytosolic E-cadherin expression in the same location was associated with locally advanced disease.

Conclusions

CXCR4 seems overexpressed at the tumor front of prostate tumors, where it potentially promotes cell migration toward the SDF-1 centrifugal attracting gradient, as well as epithelial–mesenchymal transition. High CXCR4 and low SDF-1 levels at tumor front were both associated with adverse histological features.

Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK (2002) Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62:1832–1837PubMed

Sun YX, Schneider A, Jung Y et al (2005) Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 20:318–329PubMedCrossRef

Wang L, Li CL, Yu WB et al (2011) Influence of CXCR4/SDF-1 axis on E-cadherin/beta-catenin complex expression in HT29 colon cancer cells. World J Gastroenterol 17:625–632PubMedCentralPubMedCrossRef

Schioppa T, Uranchimeg B, Saccani A et al (2003) Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 198:1391–1402PubMedCentralPubMedCrossRef

Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W (2003) Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425:307–311PubMedCrossRef

Chinni SR, Sivalogan S, Dong Z et al (2006) CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate 66:32–48PubMedCrossRef

Hirota K, Semenza GL (2006) Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol 59:15–26PubMedCrossRef

Zagzag D, Krishnamachary B, Yee H et al (2005) Stromal cell-derived factor-1 alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res 65:6178–6188PubMedCrossRef

Bachelder RE, Wendt MA, Mercurio AM (2002) Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 62:7203–7206PubMed

10.

Helbig G, Christopherson KW, Bhat-Nakshatri P et al (2003) NF-κ B promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 278:21631–21638PubMedCrossRef

11.

Wang L, Wang Z, Yang B, Yang Q, Sun Y (2009) CXCR4 nuclear localization follows binding of its ligand SDF-1 and occurs in metastatic but not primary renal cell carcinoma. Oncol Rep 22:1333–1339PubMed

12.

Speetjens FM, Liefers GJ, Korbee CJ et al (2009) Nuclear localization of CXCR4 determines prognosis for colorectal cancer patients. Cancer Microenviron 2:1–7PubMedCentralPubMedCrossRef

13.

Okera M, Bae K, Bernstein E et al (2011) Evaluation of nuclear factor kappa B and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610. BJU Int 108:E51–E58PubMedCentralPubMedCrossRef

14.

Jung SJ, Kim CI, Park CH et al (2011) Correlation between chemokine receptor CXCR4 expression and prognostic factors in patients with prostate cancer. Korean J Urol 52:607–611PubMedCentralPubMedCrossRef

15.

Singareddy R, Semaan L, Conley-Lacomb MK et al (2013) Transcriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2-ERG fusions. Mol Cancer Res 11:1349–1361PubMedCentralPubMedCrossRef

16.

Tomlins SA, Aubin SM, Siddiqui J et al (2011) Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 3:94ra72PubMedCentralPubMedCrossRef

17.

Sun YX, Wang J, Shelburne CE et al (2003) Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 89:462–473PubMedCrossRef

18.

Don-Salu-Hewage AS, Chan SY, McAndrews KM et al (2013) Cysteine (C)-x-C receptor 4 undergoes transportin 1-dependent nuclear localization and remains functional at the nucleus of metastatic prostate cancer cells. PLoS ONE 8:e57194PubMedCentralPubMedCrossRef

19.

Wang J, Krill D, Torbenson M et al (2000) Expression of cadherins and catenins in paired tumor and non-neoplastic primary prostate cultures and corresponding prostatectomy specimens. Urol Res 28:308–315PubMedCrossRef

20.

Kallakury BVS, Sheehan CE, Rhee SJ et al (1999) The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma. Cancer 85:1569–1576PubMedCrossRef

21.

Umbas R, Schalken JA, Aalders TW et al (1992) Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 52:5104–5109PubMed

22.

Tian X, Liu Z, Niu B et al (2011) E-cadherin/beta-catenin complex and the epithelial barrier. J Biomed Biotechnol 2011:567305PubMedCentralPubMed

23.

Behrens J, Vakaet L, Friis R et al (1993) Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E-cadherin/beta-catenin complex in cells transformed with a temperature-sensitive v-SRC gene. J Cell Biol 120:757–766PubMedCrossRef

24.

Taddei ML, Chiarugi P, Cirri P et al (2002) Beta-catenin interacts with low-molecular-weight protein tyrosine phosphatase leading to cadherin-mediated cell–cell adhesion increase. Cancer Res 62:6489–6499PubMed

25.

Hulsken J, Birchmeier W, Behrens J (1994) E-cadherin and APC compete for the interaction with beta-catenin and the cytoskeleton. J Cell Biol 127:2061–2069PubMedCrossRef

26.

Miyashita Y, Ozawa M (2007) Increased Internalization of p120-uncoupled E-cadherin and a requirement for a Dileucine motif in the cytoplasmic domain for endocytosis of the Protein. J Biol Chem 282:11540–11548PubMedCrossRef

27.

Palacios F, Tushir JS, Fujita Y, D’Souza-Schorey C (2005) Lysosomal targeting of E-cadherin: a unique mechanism for the down-regulation of cell–cell adhesion during epithelial to mesenchymal transitions. Mol Cell Biol 25:389–402PubMedCentralPubMedCrossRef

Title: CXCR4 is highly expressed at the tumor front but not in the center of prostate cancers
Authors: Nicolas Barry Delongchamps
Frédéric Beuvon
Jacques R. R. Mathieu
Stéphanie Delmas
Isabelle Metzger
Hervé Prats
Florence Cabon
Publication date: 01-02-2015
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 2/2015
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-014-1299-0

At a glance: The STEP trials

Springer Medicine

CXCR4 is highly expressed at the tumor front but not in the center of prostate cancers

Abstract

Objective

Patients and methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Objective

Patients and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2015

Disposable devices for RIRS: Where do we stand in 2013? What do we need in the future?

Shock wave lithotripsy: The new phoenix?

Kidney stone analysis: “Give me your stone, I will tell you who you are!”

Comparative pilot study of implantation techniques for pudendal neuromodulation: technical and clinical outcome in first 20 patients with chronic pelvic pain

Kidney stones and imaging: What can your radiologist do for you?

Metabolic disorders: stones as first clinical manifestation of significant diseases